|
Gene: RAD21 |
Gene summary for RAD21 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RAD21 | Gene ID | 5885 |
Gene name | RAD21 cohesin complex component | |
Gene Alias | CDLS4 | |
Cytomap | 8q24.11 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R9J0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5885 | RAD21 | GSM4909281 | Human | Breast | IDC | 1.21e-43 | 9.00e-01 | 0.21 |
5885 | RAD21 | GSM4909282 | Human | Breast | IDC | 3.09e-09 | 4.66e-01 | -0.0288 |
5885 | RAD21 | GSM4909285 | Human | Breast | IDC | 5.62e-05 | 2.99e-01 | 0.21 |
5885 | RAD21 | GSM4909286 | Human | Breast | IDC | 1.46e-03 | 1.85e-01 | 0.1081 |
5885 | RAD21 | GSM4909287 | Human | Breast | IDC | 4.80e-08 | 4.47e-01 | 0.2057 |
5885 | RAD21 | GSM4909288 | Human | Breast | IDC | 2.26e-03 | 1.61e-01 | 0.0988 |
5885 | RAD21 | GSM4909290 | Human | Breast | IDC | 8.74e-33 | 8.70e-01 | 0.2096 |
5885 | RAD21 | GSM4909291 | Human | Breast | IDC | 2.73e-07 | 4.83e-01 | 0.1753 |
5885 | RAD21 | GSM4909293 | Human | Breast | IDC | 9.04e-03 | 3.20e-01 | 0.1581 |
5885 | RAD21 | GSM4909295 | Human | Breast | IDC | 8.84e-08 | 5.38e-01 | 0.0898 |
5885 | RAD21 | GSM4909296 | Human | Breast | IDC | 1.75e-05 | -2.05e-01 | 0.1524 |
5885 | RAD21 | GSM4909297 | Human | Breast | IDC | 1.84e-05 | -1.34e-01 | 0.1517 |
5885 | RAD21 | GSM4909301 | Human | Breast | IDC | 5.44e-03 | 2.65e-01 | 0.1577 |
5885 | RAD21 | GSM4909304 | Human | Breast | IDC | 1.53e-05 | 2.98e-01 | 0.1636 |
5885 | RAD21 | GSM4909311 | Human | Breast | IDC | 9.89e-19 | -1.62e-01 | 0.1534 |
5885 | RAD21 | GSM4909312 | Human | Breast | IDC | 6.22e-06 | 3.07e-02 | 0.1552 |
5885 | RAD21 | GSM4909315 | Human | Breast | IDC | 4.45e-25 | 6.70e-01 | 0.21 |
5885 | RAD21 | GSM4909316 | Human | Breast | IDC | 4.29e-06 | 3.92e-01 | 0.21 |
5885 | RAD21 | GSM4909317 | Human | Breast | IDC | 1.82e-10 | 4.66e-01 | 0.1355 |
5885 | RAD21 | GSM4909318 | Human | Breast | IDC | 2.98e-03 | 5.37e-01 | 0.2031 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00519854 | Thyroid | ATC | negative regulation of chromosome segregation | 30/6293 | 45/18723 | 5.89e-06 | 6.18e-05 | 30 |
GO:19058194 | Thyroid | ATC | negative regulation of chromosome separation | 30/6293 | 45/18723 | 5.89e-06 | 6.18e-05 | 30 |
GO:001094813 | Thyroid | ATC | negative regulation of cell cycle process | 134/6293 | 294/18723 | 1.19e-05 | 1.15e-04 | 134 |
GO:004483912 | Thyroid | ATC | cell cycle G2/M phase transition | 75/6293 | 148/18723 | 1.28e-05 | 1.24e-04 | 75 |
GO:190198813 | Thyroid | ATC | negative regulation of cell cycle phase transition | 116/6293 | 249/18723 | 1.33e-05 | 1.27e-04 | 116 |
GO:001038911 | Thyroid | ATC | regulation of G2/M transition of mitotic cell cycle | 49/6293 | 94/18723 | 1.60e-04 | 1.10e-03 | 49 |
GO:000706213 | Thyroid | ATC | sister chromatid cohesion | 35/6293 | 62/18723 | 1.81e-04 | 1.23e-03 | 35 |
GO:190274911 | Thyroid | ATC | regulation of cell cycle G2/M phase transition | 51/6293 | 102/18723 | 4.45e-04 | 2.64e-03 | 51 |
GO:000630212 | Thyroid | ATC | double-strand break repair | 110/6293 | 251/18723 | 4.48e-04 | 2.65e-03 | 110 |
GO:000706413 | Thyroid | ATC | mitotic sister chromatid cohesion | 18/6293 | 28/18723 | 8.70e-04 | 4.72e-03 | 18 |
GO:000706312 | Thyroid | ATC | regulation of sister chromatid cohesion | 14/6293 | 21/18723 | 1.99e-03 | 9.54e-03 | 14 |
GO:190275011 | Thyroid | ATC | negative regulation of cell cycle G2/M phase transition | 31/6293 | 62/18723 | 5.52e-03 | 2.24e-02 | 31 |
GO:001097211 | Thyroid | ATC | negative regulation of G2/M transition of mitotic cell cycle | 30/6293 | 60/18723 | 6.27e-03 | 2.50e-02 | 30 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04110 | Colorectum | FAP | Cell cycle | 37/1404 | 157/8465 | 1.44e-02 | 4.77e-02 | 2.90e-02 | 37 |
hsa041101 | Colorectum | FAP | Cell cycle | 37/1404 | 157/8465 | 1.44e-02 | 4.77e-02 | 2.90e-02 | 37 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa041104 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
hsa0411011 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa0411022 | Oral cavity | LP | Cell cycle | 70/2418 | 157/8465 | 1.17e-05 | 8.27e-05 | 5.33e-05 | 70 |
hsa0411032 | Oral cavity | LP | Cell cycle | 70/2418 | 157/8465 | 1.17e-05 | 8.27e-05 | 5.33e-05 | 70 |
hsa0411041 | Oral cavity | EOLP | Cell cycle | 42/1218 | 157/8465 | 3.20e-05 | 1.61e-04 | 9.52e-05 | 42 |
hsa0411051 | Oral cavity | EOLP | Cell cycle | 42/1218 | 157/8465 | 3.20e-05 | 1.61e-04 | 9.52e-05 | 42 |
hsa041107 | Prostate | BPH | Cell cycle | 49/1718 | 157/8465 | 7.39e-04 | 3.59e-03 | 2.22e-03 | 49 |
hsa0411014 | Prostate | BPH | Cell cycle | 49/1718 | 157/8465 | 7.39e-04 | 3.59e-03 | 2.22e-03 | 49 |
hsa0411021 | Prostate | Tumor | Cell cycle | 51/1791 | 157/8465 | 5.67e-04 | 2.89e-03 | 1.79e-03 | 51 |
hsa0411031 | Prostate | Tumor | Cell cycle | 51/1791 | 157/8465 | 5.67e-04 | 2.89e-03 | 1.79e-03 | 51 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
RAD21 | MES | Cervix | ADJ | CENPF,TOP2A,CCNB1, etc. | 6.27e-01 | |
RAD21 | BAS | Oral cavity | Healthy | PTTG1,CCNB1,FAM98B, etc. | 1.96e-01 |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAD21 | SNV | Missense_Mutation | c.1522G>C | p.Glu508Gln | p.E508Q | O60216 | protein_coding | tolerated(0.18) | probably_damaging(0.932) | TCGA-A2-A0EW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
RAD21 | SNV | Missense_Mutation | novel | c.1627N>T | p.Asp543Tyr | p.D543Y | O60216 | protein_coding | tolerated(0.06) | possibly_damaging(0.67) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
RAD21 | SNV | Missense_Mutation | c.121N>C | p.Val41Leu | p.V41L | O60216 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
RAD21 | SNV | Missense_Mutation | c.268N>T | p.Arg90Trp | p.R90W | O60216 | protein_coding | deleterious(0) | benign(0.167) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RAD21 | SNV | Missense_Mutation | c.1485N>T | p.Glu495Asp | p.E495D | O60216 | protein_coding | tolerated(0.4) | benign(0.005) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
RAD21 | SNV | Missense_Mutation | c.1130N>G | p.Ala377Gly | p.A377G | O60216 | protein_coding | tolerated(0.25) | probably_damaging(0.978) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD | |
RAD21 | insertion | Nonsense_Mutation | novel | c.1641_1642insAGAAGAATAAATTCTAAGTCTTAAACAACAACCTCAAT | p.Asp548ArgfsTer8 | p.D548Rfs*8 | O60216 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
RAD21 | SNV | Missense_Mutation | novel | c.185N>A | p.Gly62Glu | p.G62E | O60216 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | c.1450N>C | p.Asp484His | p.D484H | O60216 | protein_coding | deleterious(0.04) | benign(0.157) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
RAD21 | SNV | Missense_Mutation | novel | c.426N>C | p.Glu142Asp | p.E142D | O60216 | protein_coding | tolerated(0.15) | probably_damaging(0.956) | TCGA-JW-AAVH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5885 | RAD21 | CLINICALLY ACTIONABLE | N/A | 15767545 |
Page: 1 |